PMLS Virtual Series 2021 – Pharmacogenomics & Pharmacovigilance in Precision Medicine
On Demand Now Click Here
March 2, 2021
Welcome & Introduction
Nigel Russell, Founder, Precision Medicine Leaders’ Summits and The Journal of Precision Medicine
Keynote – Moving Pharmacogenomics from Portrait to Landscape
Howard L. McLeod, PharmD, FASCO, FCCP, Medical Director, Precision Medicine, Geriatric Oncology Consortium; Professor, University of South Florida, Taneja College of Pharmacy
Pharmacogenomics has had rapid implementation over the past decade, with recent growth in application in oncology, mental health, solid organ transplantation, and more. With the application of panel testing, there are often additional opportunities to impact a patient’s care, beyond the specific disease focus area.
Preparing Policy: Citizen Petition for Pre-treatment DPD Testing in Patients Receiving Fluorouracil or Capecitabine Chemotherapy
Moderator: Sara Rogers, PharmD, BCPS, Director, Clinical Affairs, American Society of Pharmacovigilance
Panelists: Gabriel Brooks, PharmD, Assistant Professor, Geisel School of Medicine and Dartmouth Institute of Health Policy and Clinical Practice; Dan Hertz, PharmD, Assistant Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy; Kenneth Surprenant, MA, Patient Advocate, Retired Defense Logistics Systems Program Manager, US Department of Defense
Fluorouracil and capecitabine are widely used in the chemotherapy treatment of patients with several forms of solid tumor cancer, including gastrointestinal, head/neck and breast cancer. Dihydropyrimidine Dehydrogenase (DPD) deficiency, whether partial or complete, puts patients at risk of severe toxicity or even death when treated with FDA approved doses of fluorouracil or capecitabine. During this session, speakers will discuss progress toward universal pre-treatment DPD testing in patients receiving fluoropyrimidine chemotherapy including a citizens petition to revise the package inserts for Fluorouracil and capecitabine to recommend pre-treatment testing to identify patients with DPD Deficiency and prevent toxicity.
Incorporating PGx into Clinical Practice
Moderator: Terry McInnis, MD, MPH, CPE, Chief Medical Officer, Arine; President, Blue Thorn Healthcare Consulting
Panelists: Amber B. Cipriani, PharmD, BCOP, Coordinator, Precision Medicine Pharmacy, University of North Carolina Medical Center; Clinical Assistant Professor, UNC Eshelman School of Pharmacy; Kristine R. Crews, PharmD, FCCP, BCPS, Director, Translational Research Laboratory, St. Jude Children’s Research Hospital
Howard L. McLeod, PharmD, FASCO, FCCP; Medical Director, Precision Medicine, Geriatric Oncology Consortium; Professor, University of South Florida, Taneja College of Pharmacy; Kristin Wiisanen Weitzel, Pharm, FAPhA, FCCP, Clinical Professor, Associate Director, University of Florida Health Precision Medicine Program; Director, Graduate Program in Precision Medicine; Director, Office of Continuing Pharmacy Education
Moving from Precise to Personalized: Comprehensive Medication Management with Pharmacogenomics in Practice
Moderator: Katherine Capps, Co-founder and Executive Director, GTMRx
Panelists: Jane Cheshire Gilbert, CPA, Director, Retiree Health Care, Teachers’ Retirement System, State of Kentucky; Anthony P. Morreale, PharmD, MBA, BCPS, FASHP, Associate Chief Consultant, Clinical Pharmacy and Policy, Department of Veterans Affairs Pharmacy Benefits Management, VA Central Office
Optimizing medication use through comprehensive medication management (CMM) in practice moves us to care that is precise and personalized. Pharmacogenomics (PGx) testing makes treatment more precise. Using PGx as a tool within the CMM process makes care personalized. Integrating the two ensures we get medications right at scale, leading to better health and lower costs across populations. But, how do we do this?
To find out, join our panel discussion with Anthony Morreale, Pharm.D., associate chief consultant for clinical pharmacy services and policy at the U.S. Dept. of Veterans Affairs, and Jane Cheshire-Gilbert, CPA, director of retiree health care for the Teachers’ Retirement System of Kentucky, moderated by Katherine H. Capps, co-founder and executive director of the GTMRx Institute.
Anthony will discuss the integration of CMM within the VA while Jane will present the benefits of CMM with PGx for retirees from the health plan administrator point of view.
Overcoming the Challenges of PGx adoption in Community Care
Martin Dawes, PhD, Co-Founder and Chief Scientific Officer, GenXys Health Care Systems
Whilst the Pharmacogenetic (PGx) & Clopidogrel lawsuit and recent award to Hawaii, will help in ‘adoption out of fear’, the underlying challenges of PGx use in community care remain. We will look at some of the significant advances to remove these barriers and enable seamless PGx use in the care-workflow. This informative session is not one to miss.